从三生制药,看创新药BD的“下半场”

建国路128号
Nov 17, 2025

2025年秋,一则关于AI制药新锐“华深智药”与跨国巨头赛诺菲达成BD合作的消息,在创投圈和医药界同时刷屏。这则新闻的主角,是华深智药的CEO——朱祯平博士。两年前,当他离开三生制药这家“老牌”药企,转而投身一家从零开始的AI制药公司时,业内不乏观望与质疑。而今,朱祯平用一份扎实的BD成绩单证明,他那套追逐前沿创新项目的顶尖能力,在一个全新的平台上依然奏效。一个顶尖职业经理人的价值,在于其无可替代...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10